Apparently the deficiencies in the backup manufacturing facility for Forest Laboratories'
Mylan licensed the U.S. and Canadian rights to the drug from a Johnson & Johnson
Even with 72 million Americans suffering from high blood pressure, it will be an uphill battle for Forest's sales reps. Bystolic will have a lot of competition, with 18 other beta blockers on the market -- talk about drugmakers spinning their wheels.
Bystolic does have a slightly better side effect profile than the other beta blockers, which sometimes cause fatigue and sexual dysfunction, but that might not be enough for it to compete with generic versions of Wyeth's
Still, if Forest could eventually reach the level of U.S. sales that AstraZeneca
Nothing can beta block our Foolishness:
Glaxo and J&J are picks of the Motley Fool Income Investor newsletter. If you'd like to see more ideas for stocks that pay dividends, grab a 30-day free trial of the newsletter and check out all of our current and past recommendations.